43. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, et al. (2001) Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7: 1258–1262. 44. Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, et al. (2008) Cancer stem cells in breast: current opinion and future challenges. Pathobiology 75: 75–84. 45. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302–1313. 46. Davies JA (1996) Mesenchyme to epithelium transition during development of the mammalian kidney tubule. Acta Anat (Basel) 156: 187–201. 47. Planchard D, Soria JC, Michiels S, Grunenwald D, Validire P, et al. (2004) Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer 100: 28–35. 48. Kolodziejski L, Goralczyk J, Dyczek S, Duda K, Dymek H, et al. (1999) [Analysis of indications and results of surgical treatment for patients with pulmonary metastasis]. Pneumonol Alergol Pol 67: 228–236. 49. Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, et al. (2002) Antitumor Activity of a Recombinant Soluble Betaglycan in Human Breast Cancer Xenograft. Cancer Res 62: 4690–4695. 50. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, et al. (2004) Conditional overexpression of active transforming growth factor beta1 in vivo Doxorubicin and TGFb Inhibitor accelerates metastases of transgenic mammary tumors. Cancer Res 64: 9002–9011. 51. Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97: 834–839. 52. Martin TJ, Moseley JM (2000) Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer 7: 271–284. 53. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, et al. (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793–802. 54. Sun L, Chen C (1997) Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem 272: 25367–25372. 55. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, et al. (2003) Synthesis and activity of new aryl- and heteroaryl- substituted pyrazole inhibitors of the transforming growth factor-b type I receptor kinase domain. Journal of Medicinal Chemistry 46: 3953–3956. 56. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, et al. (2003) Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorg Med Chem Lett 13: 4355–4359. PLoS ONE | www.plosone.org 13 April 2010 | Volume 5 | Issue 4 | e10365